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INTRODUCTION
Pregnancy alters the disposition of drugs, and efforts have been made to better understand the enzyme specific changes as well as the mechanisms that cause these changes. Based on probe substrate studies, the activity of CYP3A4, CYP2C9 and CYP2D6 is increased up to 5-fold during pregnancy whereas CYP1A2 activity is decreased (Tracy et al 2005 ., Anderson, 2005 . During late pregnancy, the oral clearance of theophylline decreased by 37% (Carter et al., 1986) and concentrations of melatonin increased by 80% (Kivela, 1991) . Similarly, caffeine salivary clearance decreased by 33%, 42% and 65% during the first, second and third trimester of pregnancy, respectively (Tracy et al., 2005) . These studies suggest that the mechanisms by which pregnancy alters CYP1A2 activity differ from those leading to increased CYP3A4, CYP2C9 and CYP2D6 activity.
Some of the changes in CYP activity observed in humans have been replicated in animal models whereas others have shown discrepant results. In the mouse, Cyp3a activity and protein expression increased during pregnancy (Mathias et al., 2006; Zhang et al., 2008) whereas in pregnant rats CYP2D2 activity and mRNA decreased and CYP2C was unchanged (Dickmann et al., 2008) . The AUC of caffeine after oral administration to pregnant rats, was not different from non-pregnant rats but the AUC of theobromine and theophylline, formed by rat CYP1A2, decreased suggesting reduced CYP1A2 activity (Abdi et al., 1993) . Decreased methoxyresorufin O-demethylation was also reported during rat pregnancy with an opposing increase in CYP1A2 protein expression (Czekaj et al., 2005) . Due to these conflicting results, the aim of this study was to determine whether the decrease in CYP1A2 activity during pregnancy is due to decreased expression of CYP1A2 protein, decreased CYP1A2 mRNA, alteration of intrinsic CYP1A2 activity or competitive inhibition of CYP1A2 using the rat as a model. This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS AND METHODS
Chemicals:
Potassium phosphate, glucose-6-phosphate, glucose-6-phosphatedehydrogenase, NADPH, NADP+, magnesium chloride, caffeine, paraxanthine, theobromine and theophylline were obtained from Sigma Aldrich (St. Louis, MO).
Caffeine was purified from contaminating metabolites using an Agilent 1100 HPLC-UV system (Santa Clara, CA) equipped with an Econosphere C18 column ( 250 mm x 10 mm, 10 µm, Alltech, Deerfield, IL), using an isocratic elution with 12% 5 mM ammonium acetate and 88% methanol at 3 mL per minute. Deuterium-labeled paraxanthine was prepared by reacting D 3 -methyl iodide with 7-methylxanthine under basic conditions and purified by HPLC as described above. D 3 -theophylline and D 3 -theobromine were gifts from Tom Kalhorn and Dr. Kent Kunze (University of Washington, Seattle, WA).
Animal studies and preparation of tissue samples: The study protocol was approved by the Institutional Animal Care and Use Committee at the University of Washington and the animals were housed with free access to food and water under 12 hour light/dark cycles. Female Sprague-Dawley rats were mated at 8 weeks of age and pregnancy was determined by detection of a vaginal plug. Pregnant rats were sacrificed at midpregnancy at day 9 (n=6) and late pregnancy at day 19 (n=10). Unmated, age-matched, female rats (n=6) were used as controls. Livers were harvested, weighed, rinsed in PBS and stored at -80 º C. Microsomes were prepared from individual rat livers according to previously published methods (Rettie et al., 1989) . Total microsomal protein concentrations were measured using a Pierce BCA protein assay (Rockford, IL) according to the manufacturer's instructions using bovine serum albumin as a standard. nM -20,000 nM and resorufin production was determined using fluorescence as described above.
Analysis of CYP1A2 expression and mRNA: Protein levels of CYP1A2 were determined by Western blot as described before (Dickmann et al., 2008) donkey anti-mouse (1:5000) secondary antibodies (Rockland, Gilbertsville, PA). The fluorescence intensities were quantified on an Odyssey infrared imaging system (LICOR Biosciences). All samples were blotted in triplicate and the relative abundance of CYP1A2 protein was expressed as the CYP1A2:β-actin ratio. The antibody was confirmed to be specific towards CYP1A2 by the supplier.
Total liver RNA was isolated, quantified and reverse transcribed to cDNA as described before (Dickmann et al., 2008) . CYP1A2, β2M, 18-S-Vic and GusB transcripts were measured using commercially available TaqMan real-time PCR primers and probes with PCR Master Mix on a StepOnePlus Real-Time PCR instrument (Applied Biosystems, Foster City, CA). CYP1A2 mRNA expression in pregnant rat liver was normalized by two housekeeping genes (β2M and 18-S-Vic) using the geometric mean as described by Vandesompele, et al. (Vandesompele et al., 2002) . 
Regulation of CYP1A2 in Primary Rat
RESULTS AND DISCUSSION
Probe Validation: Caffeine metabolism to theobromine and paraxanthine and MROD were confirmed to be selective markers of CYP1A2 activity in rat liver after incubating caffeine and methoxyresorufin with a panel of rat Supersomes (data not shown). Of caffeine metabolites, theobromine instead of paraxanthine was the major metabolite observed in CYP1A2 incubations. Formation of theophylline was less selective for CYP1A2 as CYP2C6 and CYP2C11, a male specific isoform, also metabolized caffeine to theophylline. CYP2C6 and CYP2C11 also had a minor activity towards the other N-demethylation reactions. The V max and K m estimates for caffeine metabolism by CYP1A2 were 1.7 ± 0.1 pmol/min/pmol and 295 ± 42 µM (theobromine),
1.0 ± 0.1 pmol/min/pmol and 230 ± 27 µM (paraxanthine) and 0.6 ± 0.1 pmol/min/pmol and 323 ± 49 µM (theophylline), respectively. MROD appeared more specific than caffeine for CYP1A2 in the supersome panel (data not shown). The specificity of MROD as a CYP1A2 probe was confirmed in pooled RLMs. At 200 nM, α -naphthoflavone inhibited 85% of MROD demonstrating that MROD is selective for CYP1A2.
Pregnancy mediated changes in CYP1A2 activity, expression and mRNA during rat pregnancy: CYP1A2 mediated metabolism was decreased by approximately 50% during rat pregnancy regardless of the stage of pregnancy (Fig 1a) . Theobromine formation clearance decreased from 9.2 ± 2.9 nL/min/mg (control) to 4.4 ± 1.3 nL/min/mg (p < 0.01) during mid-pregnancy and to 4.8 ± 2.0 nL/min/mg (p < 0.01) during late-pregnancy. Paraxanthine formation clearance decreased from 5.4 ± 1.4 nL/min/mg to 2.7 ± 0.9 nL/min/mg (p < 0.01) at mid-pregnancy and to 2.9 ± 1.2 nL/min/mg (p < 0.01) during late-pregnancy. Theophylline formation decreased from 7.4
This article has not been copyedited and formatted. The final version may differ from this version. The V max of MROD in pooled RLMs decreased significantly (p<0.0001) from 46 ± 9.1 pmol/min/mg (control) to 21 ± 3.8 pmol/min/mg (mid-pregnancy) and 22 ± 3.8 pmol/min/mg (late-pregnancy) suggesting decreased expression of CYP1A2 or presence of a non-competitive inhibitor in the liver microsomes (Fig 1b) . The K m for MROD was significantly lower in late pregnancy than controls suggesting possible modification of CYP1A2 protein itself. In agreement with the decreased V max of MROD, the relative expression of rat CYP1A2 protein significantly decreased (ANOVA p < 0.05) during mid-and late-pregnancy to 67 ± 7.8 % (p < 0.05) and 71 ± 27 % (p < 0.05) of control rats, respectively (figure 1c). Despite the significant decrease in CYP1A2 protein expression, no change in CYP1A2 mRNA was observed in mid-pregnany and CYP1A2 mRNA decreased during late pregnancy to 73 ± 20 % (p < 0.05) of unmated controls (figure 1d). Interestingly, the greatest effect was observed in CYP1A2 activity followed by a smaller change in CYP1A2 protein expression and finally the least effect on CYP1A2 mRNA. This is of interest as with most other CYP enzymes the largest magnitude of change is observed in mRNA. It is possible that the decreased CYP1A2
protein expression during pregnancy is due to post-translational regulation rather than effects on CYP1A2 mRNA. However, during late pregnancy the magnitude of decrease in CYP1A2 mRNA was similar to the protein suggesting a contribution of transcriptional regulation as well. Based on these results it is likely that multiple mechanisms contribute to the decreased CYP1A2 activity during pregnancy. This is noteworthy as the decreased CYP1A2 activity observed in the rat is in close agreement with the 45% and 65% decrease in caffeine oral clearance during mid-and late-pregnancy (Tracy et al., 2005) .
In contrast to the gestational stage specific changes in mRNA and protein of CYP2D and CYP2C enzymes during rat pregnancy (Dickmann et al. 2008) , no significant differences were observed between gestational stages in CYP1A2 activity or expression. This finding again highlights the fact that the effects of pregnancy are specific for a given CYP enzyme, and the mechanisms that result in altered CYP expression and activity during pregnancy vary between isoforms.
Role of estrogens and progesterone in decreased CYP1A2 activity: CYP1A2 can metabolize endogenous estrogens that have been suggested as potential regulators of CYP1A2. CYP1A2 activity is lower in women than in men (Relling et al., 1992) and hormone replacement therapy (Laine et al., 1999) decrease CYP1A2 activity. Hence, the effect of 17-β-estradiol and progesterone on CYP1A2 mRNA was tested in primary rat hepatocytes, and the effect of common sex steroids as reversible CYP1A2 inhibitors was measured.
In contrast to the clinical findings, estrogens or progesterone had no effect on CYP1A2 mRNA or activity at biologically relevant concentrations. 17-β-estradiol (10, 100 or 1,000 pM) and progesterone (10, 100 and 1,000 nM) had no effect (p > 0.05) on CYP1A2 mRNA either following 24 or 48 hours of treatment except for a <15% decrease did not change CYP1A2 activity measured by phenacetin O-deethylation (data not shown), suggesting that at physiological concentrations these hormones do not inactivate CYP1A2 despite the report of increased CYP1A2 inhibition following preincubation with 300 μM progesterone (Karjalainen et al 2008) . No inhibition of MROD was observed in CYP1A2 supersomes at physiologically relevant concentrations of 17-β-estradiol, estrone, estriol and progesterone and a maximum of 40% inhibition was observed at 20,000 nM concentration of these hormones (data not shown). This is in agreement with previously determined K i of 17-β-estradiol (114 μM) and progesterone (710 μM) towards human CYP1A2 (Eugster et al 1993 ., Karjalainen et al 2008 . Therefore, downregulation or inhibition of CYP1A2 by increasing concentrations of these hormones during pregnancy is an unlikely reason for the observed decrease in CYP1A2 mediated clearance.
In conclusion, these data demonstrate that CYP1A2 protein expression is decreased during pregnancy resulting in a decreased activity of CYP1A2. This decrease occurs in rat pregnancy and mimics the changes observed in human CYP1A2 activity during pregnancy well, supporting the use of the rat as a model to study mechanisms by which CYP1A2 changes during pregnancy. The decrease in CYP1A2 mRNA was smaller in magnitude than that observed for CYP1A2 protein and activity and was only observed during late pregnancy. This suggests that mechanisms beyond regulation of CYP1A2 mRNA levels may be responsible for the early downregulation of CYP1A2 protein and require further studies. The fact that changes in CYP1A2 activity in the rat during pregnancy closely mimic those observed in humans is important when the rat is used as a model species for studying developmental toxicity of CYP1A2 substrates.
This article has not been copyedited and formatted. The final version may differ from this version. 
FOOTNOTES:
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